Press Release June 25, 2018

Akero Therapeutics Closes $65 Million Series A Financing

The Life Sciences team represented Akero Therapeutics, Inc., which announced today the completion of a $65 million Series A financing. The financing will be used to advance Akero's lead clinical program AKR-001, a novel, long-acting fibroblast growth factor 21 (FGF21) analogue. The round was co-led by Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures. Akero was founded by Apple Tree Partners.

Akero Therapeutics is advancing new medicines designed to treat serious metabolic diseases by restoring metabolic balance. The company's lead compound is AKR-001, a novel long-acting FGF21 analogue. Akero plans to begin Phase 2 clinical studies of AKR-001 for the treatment of NASH.

The Goodwin team was led by partner Laurie Burlingame and included partners Mitch Bloom, Chris Denn and Theresa Kavanaugh, and associates Gabriela Morales-Rivera, Sam Davis and Tyler Vandeventer.

For additional details, please read the press release.